TouchNEUROLOGY recently spoke with Marwan Sabbagh (Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA) to discuss the phase 2 MCLENA-1 clinical trial rationale, assessing lenalidomide in patients with mild cognitive impairment due to Alzheimer’s Disease. You can watch the interview, filmed at the 15 International Conference for Alzheimer’s & Parkinson’s Diseases (AD/PD), held online, from 8 to 14 March 2021.
